LRRC37A2 Inhibitors
Inhibitors of LRRC37A2 such as Cycloheximide and rapamycin are inhibitors of protein biosynthesis, which can lead to a decrease in the overall levels of proteins within a cell, including LRRC37A2. By inhibiting specific kinases involved in signaling pathways, such as GSK-3 beta with lithium chloride, MEK with PD98059 and U0126, p38 MAPK with SB203580, JNK with SP600125, and PI3K with LY294002, the expression of LRRC37A2 can be affected as these pathways often regulate gene expression and protein stability.
Proteasome inhibitors like bortezomib and MG132 can prevent the degradation of proteins, potentially leading to an accumulation of LRRC37A2 if it is normally subject to proteasomal degradation. Ivermectin's influence on ion channels can alter neuronal function and signaling, which may have an impact on the expression or function of LRRC37A2 in neural cells. Lastly, retinoic acid is known to regulate gene expression, and thus it can alter the transcriptional levels of a wide array of proteins including LRRC37A2.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Inhibits protein synthesis by interfering with the translocation step in protein biosynthesis, thereby potentially reducing the expression of LRRC37A2. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that can downregulate protein synthesis, likely affecting the levels of LRRC37A2. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits GSK-3 beta and modulates Wnt signaling which could alter the expression of genes including LRRC37A2. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor that can alter MAPK/ERK signaling and potentially affect the expression or function of LRRC37A2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
p38 MAPK inhibitor that can influence inflammatory response and possibly the expression of LRRC37A2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor that can affect stress response pathways and potentially modulate the expression of LRRC37A2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor that can affect various signaling pathways, potentially impacting LRRC37A2 expression or activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor that can lead to increased protein levels, potentially affecting LRRC37A2 degradation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Another proteasome inhibitor that can stabilize proteins by preventing their degradation, affecting the levels of LRRC37A2. | ||||||
Ivermectin | 70288-86-7 | sc-203609 sc-203609A | 100 mg 1 g | $57.00 $77.00 | 2 | |
Alters chloride ion channel activity and can modulate neurotransmission, possibly affecting LRRC37A2 in neural tissues. | ||||||